Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients.
In this series, antilymphoid induction therapy did not appear to be necessary to prevent early graft loss from rejection. In addition, we have followed cytomegalovirus (CMV) antigenemia (pp65) for CMV infection. Although some patients developed a positive antigenemia in the seropositive to negative donor-recipient combinations, only one patient had a prolonged febrile course for 1 week.
Corry
R J
RJ
Starzl Transplantation Institute, University of Pittsburgh, Pennsylvania, USA.
Egidi
M F
MF
Shapiro
R
R
Sugitani
A
A
Gritsch
H A
HA
Jordan
M L
ML
Dodson
S F
SF
Vivas
C A
CA
Scantlebury
V P
VP
Rao
A S
AS
Fung
J J
JJ
Starzl
T E
TE
D003920:Diabetes Mellitus / Q000601:surgery*; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D008213:Lymphocyte Activation / Q000187:drug effects; D016035:Pancreas Transplantation; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000032:analysis*
D007166:Immunosuppressive Agents; D016559:Tacrolimus